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Synaptoimmunology - roles in health and
disease
Robert Nisticò1,2* , Eric Salter3, Celine Nicolas4, Marco Feligioni2, Dalila Mango2, Zuner A. Bortolotto4,
Pierre Gressens5,6, Graham L. Collingridge3,4 and Stephane Peineau4,5,7*
Abstract: Mounting evidence suggests that the nervous and immune systems are intricately linked. Many proteins
first identified in the immune system have since been detected at synapses, playing different roles in normal and
pathological situations. In addition, novel immunological functions are emerging for proteins typically expressed at
synapses. Under normal conditions, release of inflammatory mediators generally represents an adaptive and regulated
response of the brain to immune signals. On the other hand, when immune challenge becomes prolonged and/or
uncontrolled, the consequent inflammatory response leads to maladaptive synaptic plasticity and brain disorders. In
this review, we will first provide a summary of the cell signaling pathways in neurons and immune cells. We will then
examine how immunological mechanisms might influence synaptic function, and in particular synaptic plasticity, in the
healthy and pathological CNS. A better understanding of neuro-immune system interactions in brain circuitries relevant
to neuropsychiatric and neurological disorders should provide specific biomarkers to measure the status of the
neuroimmunological response and help design novel neuroimmune-targeted therapeutics.
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Introduction
Following a pathogenic insult to the brain, most central
nervous system (CNS) cells, as well as some peripheral
immune cells, participate to the genesis of a central in-
flammation known as neuroinflammation. This process
consists of complex biochemical cascades that serve as a
protective mechanism to eliminate the initial cause of
cell injury and promote recovery. For many years it was
thought that the immune system within the CNS served
exclusively a reactive role following insults to the brain.
However, recent evidence suggests that the brain and
immune system are intimately linked and engage in signifi-
cant cross-talk under physiological, not just pathological,
conditions to preserve homeostasis. Indeed, several pro-
teins first detected in the immune system have been found
also in the healthy uninfected nervous system, where they
are having pleiotropic functions. Conversely, proteins first
described in the nervous system have since been associated
with immunological functions [1]. These factors influence
numerous physiological functions including neurite out-
growth, neurogenesis, neuronal survival, synaptic pruning,
synaptic transmission and synaptic plasticity [2]. We have
termed the interplay between immune modulators and
synaptic function, synaptoimmunology.
In this review we first provide a summary of the mech-
anisms of synaptic transmission/plasticity and immune
cell signaling pathways. Then, we discuss how these
pathways converge and thus play a role in numerous
physiological functions of synapses, with an emphasis on
synaptic plasticity. Finally, we describe how synaptoim-
munology is involved in a variety of different brain
disorders.
Synaptic communication
Synapses are the main points of rapid communication
between neurons (and in some cases between neurons
and astrocytes or microglia), through the use of chemical
neurotransmitters. This communication is subject to
alteration, a phenomenon known as synaptic plasticity:
synaptic strength can be enhanced (potentiation, P) or
reduced (depression, D). The duration of the alteration
could be transient (on the order of s and min) or more
stable (h to years) and is defined as short term (ST) or
long term (LT) respectively. Both parameters define the
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type of plasticity occurring at the synapses: LTP, LTD,
STP, STD. Mechanistically, synaptic plasticity modulates
either the function of membrane proteins (gain or loss)
or their availability (endocytosis, exocytosis, degradation,
synthesis). All these events are under the control of
multiple intracellular signaling pathways [3–5].
Neurons are also able to communicate through volume
communication, mainly via diffusing peptide molecules
(e.g., neuropeptides, cytokines, growth factors). This com-
munication can arise between neurons but also between
the different cell types of the CNS (neurons, astrocyte,
microglia, oligodendrocytes, endothelial cells, immune cell,
etc.). These peptide molecules are more slowly degraded or
captured compared to the smaller sized transmitters and
can thus diffuse far from their release site. Once they reach
their target (GPCR, kinase receptor, etc.), intracellular sig-
naling pathways are activated. On neurons, these receptors
can be located at, or in the vicinity of, synapses, where they
can directly modulate synaptic functions [6–8].
Cell signaling at synapses
The activation of intracellular signaling pathways at synap-
ses, as a response to synaptic events or diffusing molecules,
can lead to the modification of the local synaptic strength
and also a more generalized alteration in neuronal function
that often involves changes in gene expression. Conse-
quences of this signaling can therefore be restricted to a
local action mode within, or in the vicinity of, the
stimulated synapse, or can involve interactions between
the soma and synapses.
Synaptic strength is modified by synaptic plasticity events.
During LTP, some kinases cascades, such as CaMKII, have
a strict local action as they are involved in synaptic
cytoskeleton remodeling, AMPAR trafficking and/or
local protein synthesis. The PKA cascade, however, can
both affect glutamatergic receptor properties locally as
well as regulate somatic transcription and translation
[9–11]. Considerable cross-talk exists between these
different cascades. A similar scheme also exists for LTD:
PP1 or PLC cascades modify AMPAR trafficking and
internalization, whereas JAK/STAT, PI3K and eEF2K have
both local and somatic roles (Fig. 1) [3, 12].
Whilst most forms of synaptic plasticity are induced
by activation of glutamatergic receptors, synapses express
numerous other receptors including neuropeptide recep-
tors, cytokine receptors, growth factor receptors, which
represent potentially hundreds of receptors able to detect
circulating molecules. Interestingly, many of these recep-
tors engage the same signaling pathways as those involved
in synaptic plasticity. This potentially enables many ways
in which neuropeptides, and other neuromodulators,
can affect synaptic plasticity and other synaptic func-
tions (Fig. 2).
Immune system signaling
The immune system acts to defend against and restore
homeostasis following the invasion of foreign pathogens
Fig. 1 Some of the main signaling pathways in LTP and LTD. LTP involves (at different synapses) several type of receptors which include NMDA
receptor (GluN), voltage dependent calcium channel (VDCC), neurotrophin receptor (trkB), adenosine 2 receptor (A2R) or dopamine receptor (DAR).
These receptors activate intracellular signaling pathways with local and/or somatic effects, such as phosphoinositide-3 kinase (PI3K)/Akt, protein kinase
A (PKA)/ mitogen activated protein kinases (MAPK), calpain/ striatal enriched protein tyrosine phosphatase (STEP) and calcium calmodulin kinase II
(CaMKII) pathways. LTD can be triggered by the activation of, for example, GluN, VDCC and metabotropic glutamate receptors (mGlu), depending of
the form of LTD. Calcineurin (PP2B)/protein phosphatase 1 (PP1) associated to Janus kinase 2 (JAK2)/ signal transducers and activators of transcription
3 (STAT3), PI3K/Akt and glycogen synthase kinase 3 (GSK3) are mainly required for GluN dependent LTD whereas mGlu dependent LTD activates
mainly phospholipase C (PLC)/Protein Kinase C (PKC) and eukaryotic elongation factor 2 kinase (eEF2K) signaling pathways. Sequence of activation of
these pathways and inter-regulation between them are two key features to obtain synaptic plasticity events
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and tissue damage. This is achieved by the two arms of
the immune system, the innate and adaptive systems,
the former being a more rapid, nonspecific response
while the latter is slower and specific to a particular anti-
gen. Pattern Recognition Receptors (PRR) on the surface
immune cells detect damage associated molecular
patterns (DAMPs, like heat shock proteins, ATP, cell
fragments or mRNAs) released following tissue damage
as well as pathogen associated molecular patterns
(PAMPs, such as lipopolysaccharide) found on the
surface of microbes. Activation of Toll-like receptors
(TLRs), in cooperation with other PRRs, leads to the
Figu. 2 A schematic of a synapse showing pre, post elements, astrocytes and microglia. Brain and immune cells undergo a dynamic dialog.
Peripheral immune cells, such as T-lymphocytes, macrophages and dendritic cells, coming from the cerebrospinal fluid or carried by blood vessels
penetrate the brain through the blood brain barrier. They either have a surveilling activity or are attracted by the chemokines released by injured
tissues. Microglia, the brain resident immune cells, perform a constant surveilling activity and are in particular attracted by synapse activity, locus
of an intense interplay between neurons and glial cells. Many neurotransmitters circulate between these cell types resulting in the modulation of
the synaptic functions. Increasing evidence suggest that molecules and signaling pathways first discovered for the immune system takes an im-
portant place in the physiological functioning of the synapse. Growth factor receptor (GF-R); Glutamate (Glu); Gamma Amino Butyric Acid (GABA);
Acetylcholine (Ach); Dopamine (DA), Serotonin (5-HT), Adenosine tri-phosphate (ATP). (top scheme, cerebral structure inspired from [37])
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expression and release of cytokines and other inflamma-
tory molecules (TNF, IL-1β, IL-6, NO, etc.), via activa-
tion mainly of NF B, MAPK and caspase-1 [13, 14].
The factors released attract other immune cells and acti-
vate a variety of specific receptors. Depending on the re-
ceptor, different signaling pathways can be activated, all
leading to the modulation of genes regulating cell prolif-
eration or apoptosis. Cytokine receptors activate mainly
the JAK/STAT pathway [15, 16] which can either
regulate the expression of apoptotic molecules such
as Bcl-xL or cell proliferation, depending on the iso-
forms activated. Chemokines can activate GPCRs which
control the PKA/CREB signaling pathway, while growth
factors, for example, can activate PI3K/Akt and the MEK/
ERK pathway, via tyrosine receptors, to regulate gene ex-
pression [17]. There is considerable cross-talk between
these different pathways during the inflammation and
healing process.
The immune system in the CNS
Seminal experiments in the 1920s demonstrated that,
unlike peripheral tissue, engraftment of tumors into the
brain parenchyma did not elicit an immune response and
thus the tissue graft was not rejected [18, 19]. This gave
rise to the idea that the brain is an immune-privileged
organ; an idea which still holds though has been greatly
refined. Immune-privilege does not refer to an absolute
but rather relative state, and the level of immune-privilege
differs between compartments of the brain [20, 21].
In the healthy brain, the subarachnoid space, cerebro-
spinal fluid and vasculature contain circulating leukocytes
including dendritic cells, macrophages and T cells,
however the entry of these cells into the brain parenchyma
is highly restricted and regulated [21]. The brain paren-
chyma instead contains the tissue-resident macrophages
known as microglia, which are a self-renewing population
derived from yolk-sac myeloid precursor cells which
invade the CNS between E8.5 and E9.5 in mice [22]. Two
groundbreaking studies [23, 24] examined microglia
dynamics in the healthy, uninjured adult brain using in
vivo imaging and unexpectedly found that microglia pro-
cesses are continuously surveying the brain parenchyma
and are the most morphologically plastic cells in the CNS.
Additionally, microglia processes were found to contact
synapses and this interaction can be modified by neuronal
activity [25, 26]. These studies shifted the view of micro-
glia in the healthy brain from quiescence to active surveil-
lance, and gave rise to the notion that microglia play a
role in synaptic physiology. From a surveillance mode,
various stimuli can cause the microglia activation which
might lead to changes in morphology (for example, from
ramified to amoeboid), the release of cytotoxic or neuro-
protective factors (such as cytokines and growth factors),
alterations in gene and surface receptor expression, and
phagocytosis of tissue debris or pathogens [27–29].
Astrocytes are the main resident glial CNS cell popula-
tion and are the second main source of brain cytokines.
Following brain injury, astrocytes are activated and form
a reactive astrogliosis, a process important for isolating
the injured area and protect the adjacent cells but which
is deleterious for neuronal axonal regeneration [30, 31].
Astrocytes also form the glia limitans surrounding the
vasculature of the CNS and control the entry of periph-
eral immune cells into the brain parenchyma [21].
Additionally, injured neurons release factors such as
cytokines and neurotransmitters that recruit and activate
the other CNS cells involved in neuroinflammation. For
example, microglia can be activated by cytokines, by the
detection of cellular damages [13] and by neurotransmit-
ters released during injury [32]. Activated microglia
release a large array of inflammatory mediators leading
also to the recruitment of peripheral macrophages,
dendritic cells and T lymphocytes [14, 33–36] directly
from meningeal lymphatic vessels or blood vessels
[37, 38]. Astrocytes and adjacent neurons are also
activated in parallel to this cascade leading to further
factor release [39] (Fig. 2).
Most of the dialog between these different cell types is
due to factors released in the extracellular medium
(volume communication) though direct contacts are
involved in some key steps. Neurons express most of the
receptors associated with the released factors during
neuroinflammation and are sensitive to the gazotransmit-
ters or reactive oxygen species released by inflammatory
cells. It remains to be determined how the subcellular
localization of these receptors is important to modify
synaptic activity and whether they have to be present at
the modified synapse or if they can affect it at distance.
Synaptoimmunological mechanisms involved in
physiological processes
Initially believed to play a role only during inflammation
processes, increasing evidence suggest that immune signals
are essential components of normal synaptic functioning,
including roles in synaptic plasticity and stability [2].
Synaptic plasticity
Most synaptic plasticity occurs at glutamatergic synapses,
where transmission is mediated by ionotropic receptors
(GluN, GluA and GluK) and metabotropic receptors
(mGlu). Transporters, expressed on neurons and astro-
cytes, limit the activation of glutamate receptors. All these
receptors are subject to many post-translational modifica-
tions, amongst which two of the most important are
protein/protein interactions and phosphorylation.
One main role of cytokines in synaptic transmission is
their ability to modulate the induction of synaptic
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plasticity. IL-1β, IL-2, IL-6, IL-8, IL-18, IFNα, IFNγ and
TNFα have all been shown to be able to inhibit LTP and
to induce changes in hippocampal dependent learning
and memory tasks [40–42]. LTD can also be inhibited
either directly by cytokines like IL-1β or during the
inflammation process [40, 43]. Conversely, under
physiological conditions, activation of the JAK2/STAT3
pathway is required for the induction of GluN-dependent
LTD in the hippocampus [12]. Further the induction of
LTP increases the expression of IL-6 which acts in a
negative feedback manner to limit the magnitude of
potentiation [44, 45]. These results demonstrate that cyto-
kine signaling not only acts in a metaplastic manner to
modulate bidirectional changes in synaptic efficacy, but is
also part of the physiological mechanism.
The IL-1β receptor has been shown to physically inter-
act with GluN receptors enabling the rapid regulation of
GluN activity, via Src-dependent phosphorylation events
[46]. The IL-1β receptor can also decrease GluA surface
expression [47]. TNFα can promote GluA dependent
activity in hippocampal neuron and may induce GluA
internalization in striatal GABAergic neurons (reviewed
in [48]).
The mechanisms by which cytokines or inflammation
alter synaptic function is complex as microglia by them-
selves can directly facilitate synaptic strength independ-
ently of any changes in synaptic activity. Once activated,
they can, for example, induce STP via IL-1β dependent
mechanisms [49] or LTD in pathological context [50].
In addition to cytokines, major histocompatibility
complex (MHC) class I molecules also play a role in
modulating the induction of synaptic plasticity. MHC
class I molecules are a group of proteins which, within
the immune system, translocate cytosolic peptides gener-
ated by proteasome-mediated degradation to the cell
surface for recognition and subsequent cell elimination
by cytotoxic T cells [51]. MHC class I molecules have
also been found to be expressed by neurons in the CNS
and localize to synapses, axon terminals and dendrites
[52–56]. In the dorsal lateral geniculate nucleus (dLGN),
the MHC class I molecule H2-Db was found to be neces-
sary in limiting the synaptic incorporation of calcium-
permeable AMPARs and thus permit the induction of
LTD [57]. In the hippocampus, β2M−/− TAP−/− mice
(which lack cell surface expression of MHC class I mole-
cules) have a shift in LTP threshold in area CA1, such that
low-frequency stimulation, which usually induces LTD, in-
stead causes LTP, and LTP induced by high-frequency
stimulation is larger in magnitude [54, 58]. Finally, MHC
class I acts as a negative regulator of synapse density in
both the cortex and hippocampal area CA3 [59, 60],
which, in area CA3, is the result of a MHC class I-insulin
receptor complex which constrains basal insulin receptor
signaling [60].
Finally, the complement system, which is part of the
innate immune system, and in particular the complement
component C3, could also play a direct role by modulating
the efficiency of glutamatergic synaptic transmission in
the absence of any inflammation process, by a mechanism
not yet explored [61], but that could involve synaptic
stripping [62], a process initially defined as the removal of
dysfunctional synapses by activated microglia [63].
Structural plasticity
Organisms are born with an excess number of synapses
throughout the CNS, and during development superfluous
connections are removed in an experience-dependent
manner, a process known as synaptic pruning [64]. Within
the CNS synaptic pruning has been extensively studied in
the visual system, specifically the LGN and the striate cor-
tex. Initially, LGN neurons receive inputs from multiple
retinal ganglion cells (RGCs), however during postnatal
development inputs are selectively removed such that
eventually each LGN neuron only receives input from one
or two RGCs [65]. Additionally, monocular deprivation
(MD) during the developmental critical period can lead to
reduced responsiveness to the deprived eye in the LGN
and striate cortex as deprived eye inputs are weakened
[66]. Stevens and colleagues [67] found that the classic
complement cascade mediated the elimination of RGC in-
puts onto LGN neurons via microglia phagocytosis early
in postnatal development (P5). A subsequent study found
that complement-mediated synaptic pruning in the LGN
is regulated by neuronal activity, as inhibiting activity in
one eye with TTX increased microglia engulfment of that
eye’s inputs, while the converse occurred when RGC ac-
tivity in one eye was stimulated with forskolin [68]. The
developing visual system model has also revealed the in-
volvement of other immune pathways in synaptic pruning
including purinergic signaling with microglia via the
P2Y12 receptor [69] and MHC class I proteins [57].
In the developing hippocampus it has been demonstrated
that puncta of the postsynaptic protein PSD-95 are con-
tained within microglia, providing evidence of microglia-
mediated synaptic pruning. Further, knocking out the
microglia-specific fractalkine receptor CX3CR1 resulted in
an increased spine density in neonatal mice [70]. It was also
found that CX3CR1 KO mice had impaired synapse matur-
ation [70, 71], assayed by measuring the number of release
sites per neuron-neuron connection, and thus the authors
proposed that that synapse elimination allows for subse-
quent strengthening of remaining synapses [71]. However,
CX3CR1 KO mice were also found to have enhanced IL-1β
levels which resulted in a specific impairment of LTP [72],
suggesting that the effects of deficient synaptic pruning and
synapse maturation observed in CX3CR1 KO mice may
not be directly linked.
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It has been proposed that weakened synapses are
subsequently ‘tagged’ with complement proteins to
induce microglia phagocytosis [73]. Synapse elimination
has been found to occur in the hippocampus following
both mGlu- and GluN-dependent LTD [74–79]. Thus,
future studies should seek to directly examine whether
there is an interaction between synaptic depression and
microglia phagocytosis.
In the adult brain, activation of microglia leads to the
displacement of inhibitory synapses from the soma of
neurons and is neuroprotective by a mechanism involving
GluN activation [80–82]. Synaptic stripping by microglia
participates in network remodeling but its exact role in
pathology remains to be fully demonstrated [83].
Synaptic pruning can also occur independently of any
physical interaction with glia. This mechanism has been
well described for neurons with axon injury and occurs
concomitantly with glial cell activation. Astrocytes as
well as microglia release numerous factors (cytokines,
chemokines, thrombospondins, etc.) that directly influence
synapse integrity [84, 85].
Though research has mainly focused on microglia in
relation to synapse elimination, recent advances have
shed light on the role microglia also play in spine forma-
tion. The generation of CX3CR1-CreER mice allowed
Parkhurst and colleagues [86] to conditionally deplete
microglia or knockout microglial BDNF. Subsequent in
vivo two photon imaging revealed that these manipula-
tions impaired spine formation in the motor cortex fol-
lowing motor learning. Furthermore, in vivo two photon
imaging of the somatosensory cortex of developing mice
revealed that microglia contact of dendrites frequently
led to spine filipodia formation [87]. Therefore, it ap-
pears that microglia can cause bidirectional modifica-
tions of dendrite spine structure but the underlying
mechanisms (see also the review of Kettenman et al.
[63]) involved in this process need more investigation by
future studies.
Synaptic scaling
At glutamatergic synapses, when extended periods of el-
evated or depressed neuronal activity occur, homeostatic
mechanisms can be activated. They alter strength across
all synapses to return activity to an optimal range, a
process known as synaptic scaling [88]. Chronic (24–48 h)
blockade of neuronal action potential firing or glutamater-
gic synaptic transmission results in a large increase in
mEPSC amplitude (a putative measure of post-synaptic
sensitivity to glutamate) as well as the number of surface
AMPARs [89]. Stellwagen and Malenka [90] found that
TNFα is both necessary and sufficient for scaling up of
post-synaptic AMPARs. Interestingly, although both neu-
rons and glia are capable of producing TNFα, the authors
found that it is the glia-released TNFα that is critical for
scaling up of synapses. A subsequent study found that β3
integrins are also necessary for scaling up of synapses, and
that TNFα application increases the surface expression of
β3 integrin [91]. Further, the authors found that levels of
β3 integrin control surface AMPARs and thus mEPSC
amplitude, suggesting a model in which glial cells, in
response to reduce network activity, release TNFα leading
to an increase in β3 integrin surface expression and
subsequent accumulation of AMPARs at the synapse [92].
To address the physiological significance of TNFα-
meditated synaptic scaling, Kaneko and colleagues [93]
examined visual system. In the striate cortex, similar to
the hippocampus, LTP was normal in TNFα−/− mice,
however scaling up of AMPAR-mediated mEPSCs was
absent. In vivo, TNFα−/− mice had impaired ocular
dominance plasticity following MD, specifically having a
complete deficit in the increase of non-deprived eye cor-
tical response, despite a normal decrease in the cortical
response for the deprived eye. Thus, synaptoimmunolo-
gical factors are critical for both phases of ocular domin-
ance plasticity, with the complement cascade mediating
the loss of cortical responsiveness to the deprived eye,
while TNFα mediates the compensatory, homeostatic
increase in non-deprived eye cortical responsiveness.
Synaptoimmunological mechanisms involved in
acute brain disorders
Causes of brain disorders associated with neuroinflamma-
tion and synaptic function alteration are numerous. Some
disorders appear following a brief episode associated an
infection, whereas others have either undefined causes
or genetic origins. The mechanisms involved in synaptic
function alteration are dependent of the nature of the
cause.
Acute infection
Following a systemic or a direct brain infection, an im-
munological response is triggered and coordinated by the
brain and the immune system. In general acute and long-
term infections of the brain and spinal cord are produced
mostly by traumatic injury, parasites, intoxication and sys-
temic infectious diseases caused by viruses, bacteria, fungi
and parasites, which penetrate the central nervous system.
A common and potentially life-threatening form of gener-
alized inflammatory response is sepsis, which is character-
ized by an overreaction of the immune system. The
pathophysiology of the sepsis is highly complex and affects
all types of brain cells and brain functions (for a compre-
hensive review of sepsis and brain dysfunctions see [94]).
Brain viral infections (e.g., by influenza, HIV, Herpes,
West Nile virus (WNV) has been reported to both directly
and indirectly (by promoting neuroinflammation) affect
synaptic functions, leading to cognitive impairment
[95–97]. For example, a recent study found that
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synapse loss in a mouse model of WNV infection is
driven by the activation of the classical complement
cascade in the hippocampus [62]. Further, various viral
proteins reduce voltage dependent calcium channel [98]
or GluA function [99]. Interestingly some viral effects re-
quire NMDAR activation or alteration through PKA and
PKC dependent mechanisms (for a review see [96]). Add-
itionally, certain viral dependent synapse impairments are
also explained by the ability of viruses to indirectly induce
the expression or interfere with the function of proteins
associated with synaptic impairment like Aβ or APP [100].
Acute brain injuries without pathogen
Acute brain injuries are often associated with an inflamma-
tion response in the absence of any pathogen, a mechanism
termed sterile inflammation, which can be caused by mul-
tiple different events such as mechanical trauma, ischemia,
stress, alcohol etc.. Three of the main pathologies arising
from these sterile injuries are Traumatic Brain Injuries
(TBI), epilepsy and stroke, pathologies which share com-
mon cell death mechanisms [101]. This inflammation has
been associated both with the worsening of the pathologies
and with the repair phase [101–104], but the mechanisms
involved in the alteration of synapse functions could be
pathology-specific.
Synapses, by their intrinsic complex architecture in-
cluding PSD and adhesion molecules, contribute largely
to the diffusion of mechanical trauma during TBI [105]
suggesting that inflammation dependent alteration of
synapse integrity may be directly involved in the severity
of the pathology.
Epilepsy and inflammation are strongly linked (reviewed
in [106]). Synapse elimination, sprouting and changes in
synaptic strength are key features of this pathology.
Inflammation impacts epilepsy directly by modulating
synaptic activity via altered protein expression through
the activation of the NFκB pathway or by altering
synaptic channel activity via phosphorylation cascades
[107]. Computational network modeling has also pre-
dicted that TNFα release by glia following inflammation
can lead to epileptogenesis through scaling up of synap-
ses [108].
The effect of sterile inflammation on synaptic function
may also depend of changes in neuronal environment
during pathology. Thus TNFα enhances LTP in the con-
text of ischemia via a p38 MAPK dependent mechanism,
whereas it blocks LTP in the physiological context [109].
The alteration of glutamatergic transmission disappears
when inflammation resolved [40].
Another prominent cause of brain inflammation is al-
cohol abuse, as illustrated by the phenomenon of “binge
drinking” [110]. It is well documented that alcohol directly
affects glutamate receptors (GluRs) and other families of
receptors [111–117] as well as synaptic plasticity [118].
Critically several studies in humans [113, 119, 120] and
animals [121–124] have provided strong evidence that
the effect of alcohol abuse on GluRs harms brain de-




In recent years, the classical dichotomy between inflamma-
tion and neurodegeneration has been challenged by evi-
dence suggesting that both aspects are interconnected both
in neurodegenerative diseases, including Alzheimer’s dis-
ease (AD) and Parkinson’s disease (PD), and in traditional
neuroinflammatory disorders, such as multiple sclerosis
(MS) [125, 126]. Growing experimental evidence suggests
that synapses may be the locus for abnormalities underlying
these diseases. Indeed, perturbations in the induction,
maintenance or reversal of LTP and LTD are a common
thread in the different brain disease models [127, 128], as
well as in human pathologies associated with inflammation
[129]. However, there are disease-specific mechanisms of
how synapse structure and function are precisely affected
in each disorder. It is thus reasonable to postulate that the
combination of abnormal expression of immune mediators
along with other disease-specific features might contribute
to the distinct etiopathogenesis of different conditions.
Multiple sclerosis/EAE
Multiple sclerosis (MS), especially its relapsing-remitting
form, is a complex immune-mediated disease [130]. The
neuroinflammatory milieu that typically characterizes
MS profoundly impacts the capability of neuronal systems
to express normal plasticity, possibly leading to a state of
decreased homeostatic reserve with negative consequences
on cognitive performances. Inflammation-induced synaptic
dysfunction appears in the very early phases of MS patients
and in the experimental autoimmune encephalomyelitis
(EAE), a well-established mouse model of multiple scler-
osis. Accordingly, it was recently shown that intermittent
(iTBS) or continuous theta burst stimulations (cTBS), de-
livered through a transcranial magnetic stimulation (TMS)
device, modulate the expression of cortical plasticity in the
acute inflammatory phases of MS patients. In general, LTP
was always favored over LTD in response to repetitive syn-
aptic activation in MS brains, and this effect was directly
correlated with IL-1β levels in the CSF [129]. Similar re-
sults were also observed in hippocampal slices from EAE
mouse, in which the facilitation of CA1-LTP was also me-
diated via enhanced IL-1β released from CD3+ T lympho-
cyte infiltrates or activated microglia, clearly detectable in
the EAE hippocampus [43, 131]. Remarkably, preventive or
pharmacological strategies restraining pro-inflammatory
cytokines and oxidative stress were able to rescue synaptic
alterations in the EAE model [132, 133].
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Alzheimer’s disease
AD is a chronic neurodegenerative disease character-
ized by progressive neuronal loss and cognitive de-
cline. Oligomeric amyloid β (oAβ) is implicated in the
pathogenesis of AD and disrupts synaptic plasticity
through numerous mechanisms (Fig. 3) [127]. Inflam-
matory features including activation and proliferation
of glia and expression of mediators such as IL-1, IL-6,
and TNFα [133, 134] have been clearly detected in
the brain, CSF and peripheral blood of AD patients.
These molecules are linked to immune cell activa-
tion and strongly affect LTP, even though the rela-
tion between oAβ and inflammation remains unclear.
Regardless, it is conceivable that the ‘early’ loss of
Fig. 3 Signaling pathways in inflammation / immune response and how genetic risk factors for (e.g. AD) may impact via these pathways.
Oligomeric or aggregate of amyloid beta peptides (Aβ), as occurring during Alzheimer’s disease, are detected by pattern recognition receptor
(PRR) like Toll like receptors. In microglia they stimulate the production and release of cytokines such as interleukins (IL). These interleukins are
detected by astrocytes and neurons, where they stimulate signaling pathways that interfere directly with the signaling pathways activated during
synaptic plasticity, inducing deficits in LTP or exacerbated LTD. Aβ peptides can also interfere directly with neurotransmitter receptors (Glutamate
receptors (GluN, mGlu) or acetylcholine receptors) leading to abnormal neurotransmission. (top scheme, cerebral structure inspired from [37])
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hippocampal LTP observed in AD represents a
downstream effect of the presence of both oAβ and
ongoing neuroinflammation.
Among cytokines, TNFα and IL-1β have been shown
to mediate the detrimental effects of oAβ on LTP. Indeed,
suppression of LTP by oAβ was absent in mutant mice
null for TNF receptor type 1 and was prevented by the
monoclonal antibody infliximab, the TNF peptide antag-
onist, and thalidomide, the inhibitor of TNFα production
[135]. Further, intracerebroventricular administration of
interleukin 1 receptor antagonist (IL-1ra) rescued post-
tetanic potentiation impairment following injection of
oAβ peptide [136].
To further support a role for inflammation in AD,
evidence from epidemiologic studies and clinical tri-
als suggest that non-steroidal anti-inflammatory agents
(NSAIDs) exert neuroprotection in AD. Accordingly,
two selective COX-2 inhibitors were effective in pre-
venting the disruption of LTP by synthetic soluble
Aβ [137].
An emerging issue is how microglia, which physiologic-
ally control synapse function and plasticity, contribute to
AD pathogenesis. Recent evidence suggests that failure of
signaling required for maintaining a ‘resting’ microglial
phenotype, likely important for preserving surveillance
functions, might have profound consequences on synaptic
activity. For instance, numerous studies have found that
Aβ increases microglia activation and the release of cy-
tokines which impair LTP, and that inhibiting microglia
activation can prevent the block of LTP induction by
Aβ (for a recent review see [138]). Further the loss of
synapses, a hallmark feature of AD, has been linked to
microglia phagocytic activity. A recent study found that
synapse loss in the hippocampus in the early stages of a
mouse model of AD, as well as following direct infusion
of oAβ, was mediated by the complement cascade (C1q,
C3 and CR3). Thus the authors suggest that microglia-
mediated synapse loss early in AD may be due to a
pathological reactivation of a developmental program
of synaptic pruning [139].
Parkinson’s disease
Similar to the synaptotoxic role played by oAβ in AD,
extracellular alpha-synuclein oligomers also modulate
synaptic transmission and impair LTP [140]. However,
results obtained in this study are questionable since
alpha-synuclein oligomers were applied at supraphysio-
logical concentrations. Aggregation of α-synuclein trig-
gers the release of TNFα and IL-1β from microglia, and
this might lead to its toxic effects on dopaminergic cells
[141]. Several authors found elevated TNF, IL-1, IL-6,
IL-2 and upregulation of MHC molecules in the stri-
atum and CSF of PD patients [142], thus supporting the
hypothesis that immune response is a pathogenic
mechanism underlying PD. Notably, treatment with the
flavonoid baicalein decreased upregulation of TNFα and
IL-1β and normalized striatal glutamatergic transmission
in a rodent model of PD [143]. Presence of a persistent
active inflammatory process in PD patients might
contribute to the impairment of physiological synaptic
plasticity at corticostriatal synapses. This, in turn, might
lead to disruption of signaling pathways within the
basal ganglia neuronal network [144] as the basis of PD
symptomatology.
Further studies are still required to clarify the precise
role that cytokines might play in striatal synaptic plasti-
city in physiological and pathological conditions.
Therapeutic implications and conclusions
During the course of an immune attack, release of
pro-inflammatory cytokines is temporary and normally
controlled by anti-inflammatory mechanisms, repre-
senting an adaptive and regulated response of the brain to
immune signals. Conversely, when the immune challenge
becomes prolonged and/or uncontrolled, the conse-
quent inflammatory response might lead to pathological
conditions.
Despite remarkable progress in the knowledge of cell
signaling in neuroimmunology, to date several key ques-
tions still need to be addressed. For example, whereas
immune protein function has been well characterized
within the immune cells, not as much is known about
how immune proteins exert their non-immune role to
influence signaling pathways and gene expression en-
gaged in synaptic plasticity in neurons. Next, it is still
unclear how pathways are precisely activated by cytokines
in target cells within a physiological or pathological set-
ting. One critical issue might relate to the different con-
centrations of cytokines between the in vitro and in vivo
condition. In fact, cytokines are generally used within the
nanomolar range in vitro, whereas their in vivo levels in
the brain fall within the picomolar range, making it diffi-
cult to define the realistic cytokine exposure at the synap-
tic level following different stimuli.
Considering the importance of immune mechanisms
on neurotransmitter systems and brain circuitries relevant
to neuropsychiatric diseases, a better understanding of
brain-immune system interactions will hopefully provide
specific biomarkers to measure the status of the neuroim-
munological response, as well as novel neuroimmune-
targeted therapeutics.
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